Hello, everyone, and how are you today? We are in fine spirits because we are about to start a brief holiday. We promised the short people we would spend time with them while the schoolhouse is closed this week and we will not let them down. However, we are trying an experiment. Rather than close shop for a couple of days, in our absence, a colleague from the vast UBM reserves will keep watch and attempt to fill in for us. That said, you may not see the same volume of material as usual. We hope you understand. Even we need a break now and then. Nonetheless, we will check e-mail, so if you have an itch to forward a concern or a hot tip, our 'in basket' remains open for business. Meanwhile, here are some tidbits. Have a grand day and see you soon...
Glaxo Insists It Is The Best Owner For Human Genome (Reuters)
Amgen Buys Turkish Drugmaker For $700M (Associated Press)
Icahn And Amylin Have May 10 Hearing For Proxy War (GenEn News)
Sanofi Drug Improves Disability Scores In MS Patients (Bloomberg News)
ViroPharma Loses Bid To Block Generic Vanconin (Philadelphia Business Journal)
Amgen Profit Beats Estimates Thanks To Rising Sales (Bloomberg News)
Botox Offers Little Migraine Relief: Study (HealthDay News)
Spain Will Start Charging Seniors For Drugs (Pharma Times)
EDITOR'S NOTE: Please check this post for updates throughout the morning